Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35005838/
Uniform flow cytometry data analysis substantially reduced inter-laboratory variation in reporting multiple components of the MM MRD assay. Adoption of a harmonized approach would meet an important need for conformity...
Conclusion: Uniform flow cytometry data analysis substantially reduced inter-laboratory variation in reporting multiple components of the MM MRD assay. Adoption of a harmonized approach would meet an important need for conformity in reporting MM MRD for clinical trials, and wider acceptance of MM MRD as a surrogate clinical endpoint.
Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35026836/
Persistence of minimal residual disease (MRD) after induction/consolidation therapy in acute lymphoblastic leukemia is the leading cause of relapse. The GMALL 07/2003 study used MRD detection by RQ-PCR of clonal...
Conclusion/Relevance: "Within the GMALL 07/03 study, 1019 consecutive bone marrow samples after first consolidation were evaluated for MRD. Patients with complete molecular response had significantly better outcome (five-year overall survival, 5y-OS=85±2%, n=603; five-year disease-free survival, 5y-DFS=73±2%, n=599) compared to patients with...
Blinatumomab In pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34979020/
2022 Jan 3;bloodadvances.2021005579. doi: 10.1182/bloodadvances.2021005579. Online ahead of print. 1 Bambino Gesù Children's Hospital, Sapienza University of Rome, Rome, Italy. 2 Amgen Research, Munich, Germany. 3 Amgen Research (Munich) GmbH,...
Conclusion/Relevance: These findings support the use of blinatumomab as a safe and efficacious treatment for pediatric R/R B-ALL.
Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34938662/
Chimeric antigen receptor T-cell (CAR-T) therapy targeted against B-cell maturation antigen (BCMA) in multiple myeloma (MM) has produced rapid responses but many eventually relapse. In light of this new treatment,...
Conclusion: In conclusion, achieving a nonelevated iFLC and an undetectable MRD-NGS quickly were factors that were strongly associated with improved PFS. Further studies are needed to confirm the role of these markers in MM patients receiving CAR-T therapies.
Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent
Source : https://ascopubs.org/doi/10.1200/JCO.21.01929
Circulating tumor DNA (ctDNA) minimal residual disease (MRD) is a powerful biomarker with the potential to improve survival outcomes for non-small-cell lung cancer (NSCLC). Multiple groups have shown the ability...
Conclusion/Relevance: Circulating Tumor DNA Minimal Residual Disease Detection of Non–Small-Cell Lung Cancer Treated With Curative Intent